Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fresh Frozen Plasma for Thrombocytopenia in Dengue
NCT06642493Active, not recruiting
- Sponsor
- Sheikh Hasina National Institute of Burn and Plastic Surgery
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
Randomised, open-label trial of fresh-frozen plasma in dengue fever, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (2 arms), sponsored by Sheikh Hasina National Institute of Burn and Plastic Surgery. Primary endpoint: Activated Partial Thromboplastin Time at 48 hours. Started May 2024; status: active, not recruiting.
02
Drugs
fresh-frozen plasma
03
Conditions
dengue feverdengue hemorrhagic fever (DHF)dengue shock syndrome (DSS)
Beyond the preview
Go deeper on NCT06642493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642493.